LMAT · LeMaitre Vascular, Inc.
$98.93
+3.41% last session
End-of-day data · updated 2026-07-29
Market cap
$2B
Enterprise value
$2B
Trailing P/E
37.6
Forward P/E
31.4
Dividend yield
1.0%
Beta
0.52
Avg volume
0M
Employees
1K
2D change
3.41%
5D change
—
10D change
0.66%
30D change
6.56%
60D change
8.08%
MTD change
3.61%
YTD change
26.74%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LMAT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-03
Latest call per bank · past 12 months
Wells Fargo
Equal-Weight$104
+5.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-03 | Barrington Research | Maintains | Outperform | $120 |
| 2026-05-06 | Barrington Research | Maintains | Outperform | $105 → $120 |
| 2026-05-06 | Citizens | Maintains | Market Outperform | $118 → $127 |
| 2026-05-06 | Wells Fargo | Maintains | Equal-Weight | $94.00 → $104 |
| 2026-02-26 | Barrington Research | Maintains | Outperform | $95.00 → $105 |
| 2026-02-26 | Roth Capital | Reiterates | Buy | $108 → $117 |
| 2026-02-26 | Wells Fargo | Maintains | Equal-Weight | $87.00 → $94.00 |
| 2026-02-26 | Citizens | Maintains | Market Outperform | $113 → $118 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.3% above the 50-day MA ($97.15).
- Price vs 200-day MA: Trading 7.7% above the 200-day MA ($95.01).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.17) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($79.79) and high ($117.10).
LMAT Price Chart
Loading chart for LMAT…
Fundamentals
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$130B -36.1% YTD
MDLN
Medline Inc.
$72B -3.5% YTD
BDX
Becton, Dickinson and Company
$46B 10.5% YTD
ALC
Alcon Inc.
$34B -11.9% YTD
RMD
ResMed Inc.
$30B -12.8% YTD
WST
West Pharmaceutical Services, I
$24B 22.7% YTD
SOLV
Solventum Corporation
$15B 8.8% YTD
COO
The Cooper Companies, Inc.
$14B -12.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.